C4 Therapeutics shares surge 10.57% intraday as biotech sector gains momentum and its protein degradation therapies attract attention.

miércoles, 7 de enero de 2026, 10:33 am ET1 min de lectura
CCCC--
C4 Therapeutics surged 10.57% in intraday trading, driven by an overall increase in the biotech sector's appeal, as highlighted by a Citi analyst report indicating a 32% rise in the Nasdaq Biotechnology Index by 2025 and potential valuation recovery by 2026. The company specializes in protein degradation therapies through its TORPEDO platform and BIDAC/MONODAC products, which are currently in high demand.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios